Search Result

Results for "

CDK9 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (187) Androgen Receptor (1) Antibiotic (2) Apoptosis (69) Atg8/LC3 (1) Aurora Kinase (2) Autophagy (1) Bcl-2 Family (11) BCL6 (1) Biochemical Assay Reagents (1) c-Myc (13) Casein Kinase (2) Caspase (6) Cholinesterase (ChE) (1) CMV (5) COX (1) DNA/RNA Synthesis (13) Drug Isomer (4) DYRK (2) EGFR (5) Epigenetic Reader Domain (1) ERK (1) FLT3 (2) Fungal (2) GSK-3 (6) HDAC (3) Histone Methyltransferase (1) HIV (5) HSV (2) IAP (2) Interleukin Related (1) IRE1 (2) Isotope-Labeled Compounds (1) JAK (3) Ligands for Target Protein for PROTAC (4) MEK (2) Molecular Glues (2) PARP (6) PKC (1) PROTACs (8) Reactive Oxygen Species (ROS) (3) Reference Standards (14) SARS-CoV (2) STAT (1) Virus Protease (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (179) Endocrinology (1) Infection (13) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (3)

By Targets:

CDK (187)

Androgen Receptor (1)

Antibiotic (2)

Apoptosis (69)

Atg8/LC3 (1)

Aurora Kinase (2)

Autophagy (1)

Bcl-2 Family (11)

BCL6 (1)

Biochemical Assay Reagents (1)

c-Myc (13)

Casein Kinase (2)

Caspase (6)

Cholinesterase (ChE) (1)

CMV (5)

COX (1)

DNA/RNA Synthesis (13)

Drug Isomer (4)

DYRK (2)

EGFR (5)

Epigenetic Reader Domain (1)

ERK (1)

FLT3 (2)

Fungal (2)

GSK-3 (6)

HDAC (3)

Histone Methyltransferase (1)

HIV (5)

HSV (2)

IAP (2)

Interleukin Related (1)

IRE1 (2)

Isotope-Labeled Compounds (1)

JAK (3)

Ligands for Target Protein for PROTAC (4)

MEK (2)

Molecular Glues (2)

PARP (6)

PKC (1)

PROTACs (8)

Reactive Oxygen Species (ROS) (3)

Reference Standards (14)

SARS-CoV (2)

STAT (1)

Virus Protease (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (179)

Endocrinology (1)

Infection (13)

Inflammation/Immunology (8)

Metabolic Disease (2)

Neurological Disease (3)

194

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: CDK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10492

Dinaciclib Maximum Cited Publications 54 Publications Verification SCH 727965	CDK Apoptosis	Cancer
Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC₅₀s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and *CDK9*, respectively .

HY-112088

AZD4573 10+ Cited Publications	CDK	Cancer
AZD4573 is a potent and highly selective *CDK9* inhibitor (IC₅₀ of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies .

HY-10008

SNS-032 10+ Cited Publications BMS-387032	CDK Apoptosis	Cancer
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and *CDK9* with IC₅₀s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect .

HY-101212

Fadraciclib 5+ Cited Publications CYC065	CDK	Cancer
Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of *CDK2/CDK9* kinases with IC₅₀s of 5 and 26 nM, respectively .

HY-103248

Toyocamycin 5+ Cited Publications Vengicide	IRE1 Fungal Antibiotic Apoptosis CDK	Infection Cancer
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC₅₀ value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits *CDK9* with an IC₅₀ value of 79 nM .

HY-13461

PHA-767491 4 Publications Verification CAY10572	CDK	Cancer
PHA-767491 is a dual *Cdc7/Cdk9* inhibitor, with IC₅₀s of 10 nM and 34 nM, respectively.

HY-12214A

NVP-2 40+ Cited Publications	CDK Apoptosis	Cancer
NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC₅₀ of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC₅₀ values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces cell apoptosis.

HY-13914

Roniciclib 2 Publications Verification BAY 1000394	CDK	Cancer
Roniciclib is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC₅₀s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.

HY-50940

AT7519 10+ Cited Publications AT7519M	CDK Apoptosis	Cancer
AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-12445

Asnuciclib 2 Publications Verification CDKI-73; LS-007	CDK Apoptosis	Inflammation/Immunology Cancer
Asnuciclib (CDKI-73; LS-007) is an orally active and highly efficacious *CDK9* inhibitor, with K_i values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. Asnuciclib down-regulates the RNAPII phosphorylation. Asnuciclib is also a novel pharmacological inhibitor of Rab11 cargo delivery and innate immune secretion .

HY-137478

KB-0742 3 Publications Verification	CDK	Cancer
KB-0742 is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 has potent anti-tumor activity .

HY-15878

LDC000067 10+ Cited Publications LDC067	CDK Apoptosis	Cancer
LDC000067 is a highly specific *CDK9* inhibitor with an IC₅₀ value of 44±10 nM in vitro.

HY-173523

KI-CDK9d-32	PROTACs CDK c-Myc	Cancer
KI-CDK9d-32 is a highly selective and potent *CDK9* PROTAC degrader (DC₅₀: 0.89 nM). KI-CDK9d-32 promotes the ubiquitination and degradation of CDK9. KI-CDK9d-32 inhibits the MYC pathway and disrupts nucleolar homeostasis. KI-CDK9d-32 exhibits anticancer activity against acute lymphoblastic leukemia and pancreatic cancer. (Pink: CDK9 ligand (HY-153718); Blue: E3 ligase CRBN ligand (HY-163233); Black: Linker (HY-W011657); E3 ligase CRBN ligand-linker conjugate (HY-173525)) .

HY-103019A

(±)-Enitociclib (±)-BAY-1251152; (±)-VIP152	CDK Apoptosis DNA/RNA Synthesis	Cancer
(±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective *CDK9* inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-124639

CDK9 inhibitor HH1	CDK	Cancer
CDK9 inhibitor HH1 is a potent and selectively *CDK9* inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer .

HY-12871B

Atuveciclib 5+ Cited Publications BAY-1143572	CDK	Cancer
Atuveciclib (BAY-1143572) is a potent and highly selective, oral *PTEFb/CDK9* inhibitor. Atuveciclib (BAY-1143572) inhibits *CDK9/CycT1* with an IC₅₀ of 13 nM .

HY-12871

Atuveciclib Racemate 1 Publications Verification BAY-1143572 Racemate	CDK	Cancer
Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral *P-TEFb/CDK9* inhibitor which supresses *CDK9/CycT1* with an IC₅₀ of 13 nM.

HY-137478A

KB-0742 dihydrochloride 3 Publications Verification	CDK	Cancer
KB-0742 dihydrochloride is a potent, selective and orally active *CDK9* inhibitor with an IC₅₀ of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity .

HY-162919

YK-2168	CDK Apoptosis c-Myc	Cancer
YK-2168 is a potent and selective *CDK9* inhibitor with an IC50 of 5.9 nM. YK-2168 inhibits phosphorylation of the CDK9 substrate pS2-RNA Pol II C-terminal domain. YK-2168 induces apoptosis in tumor cells, suppresses expression of CDK9-regulated genes including MYC and Mcl1, and inhibits tumor growth in CDX mice models. YK-2168 can be used for the research of cancer, such as leukemia .

HY-13461A

PHA-767491 hydrochloride 4 Publications Verification CAY-10572 hydrochloride	CDK Apoptosis	Cancer
PHA-767491 hydrochloride is a dual *Cdc7/Cdk9* inhibitor, with IC₅₀s of 10 nM and 34 nM, respectively.

HY-X0150

JSH-150 1 Publications Verification	CDK	Cancer
JSH-150 is a highly selective and potent *CDK9* inhibitor with an IC₅₀ of 1 nM.

HY-119940

MC180295 1 Publications Verification (rel)-MC180295	CDK	Cancer
MC180295 ((rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC₅₀ of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect .

HY-50943

AT7519 Hydrochloride 10+ Cited Publications	CDK Apoptosis	Cancer
AT7519 Hydrochloride is a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-12293

LY2857785 4 Publications Verification	CDK Apoptosis	Cancer
LY2857785 is a type I reversible and competitive ATP kinase inhibitor against *CDK9* (IC₅₀ 11 nM) and other transcription kinases CDK8 (IC₅₀ 16 nM), and CDK7 (IC₅₀ 246 nM).

HY-13231

CDK9-IN-1 1 Publications Verification	CDK HIV	Infection
CDK9-IN-1 is a novel, selective *CDK9* inhibitor for the treatment of HIV infection, with an IC₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

HY-100429

CAN508 1 Publications Verification	CDK	Cancer
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity .

HY-153260

TP-1287	CDK	Cancer
TP-1287, a prodrug of Alvocidib (HY-10005), is an orally active *CDK9* inhibitor .

HY-141687

NSC 107512 1 Publications Verification	CDK Apoptosis	Cancer
NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors .

HY-103019B

(-)-Enitociclib 2 Publications Verification (R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152	Drug Isomer CDK Apoptosis DNA/RNA Synthesis	Cancer
(-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective *CDK9* inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-139980

CDK9-IN-13	CDK	Cancer
CDK9-IN-13 (compound 38) is potent and selective *CDK9* inhibitor, with an IC₅₀ of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents .

HY-102039

CDK9-IN-8	CDK	Cancer
CDK9-IN-8 is a highly effective and selective *CDK9* inhibitor with an IC₅₀ of 12 nM.

HY-16462

CDK9-IN-2 5+ Cited Publications	CDK	Cancer
CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC₅₀ of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.

HY-50940A

AT7519 TFA 10+ Cited Publications AT7519M TFA	CDK	Cancer
AT7519 (AT7519M) TFA as a potent inhibitor of CDKs, with IC₅₀s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

HY-156084

LL-K9-3	CDK PROTACs Apoptosis c-Myc	Cancer
LL-K9-3 is a potent small-molecule degrader of CDK9-cyclin T1. LL-K9-3 has anti-proliferative and pro-apoptotic activities and suppresses downstream signaling of CDK9 and AR. Moreover, LL-K9-3 inhibits AR and Myc-driven oncogenic transcriptional programs .

HY-12871C

Atuveciclib S-Enantiomer BAY-1143572 S-Enantiomer; (+)-Atuveciclib; (+)-BAY-1143572	CDK	Cancer
Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective *CDK9* inhibitor, which inhibits *CDK9/CycT1* with an IC₅₀ of 16 nM.

HY-176165

CDK9/EZH2-IN-1	CDK Histone Methyltransferase	Cancer
CDK9/EZH2-IN-1 (Compound D16) is a *CDK9/EZH2* dual-target inhibitor (IC₅₀: 83.9/108.6 nM). CDK9/EZH2-IN-1 induces apoptosis and DNA double-strand breaks (DSBs). CDK9/EZH2-IN-1 inhibits the proliferation activity of MKN45, MDA-MB-453 and SW620 cancer cells (IC₅₀ values are 136.3, 171.3 and 315.7 nM, respectively) .

HY-126251

CDK9-IN-7	CDK Apoptosis	Cancer
CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC₅₀=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC .

HY-100950

ABC1183	GSK-3 CDK	Inflammation/Immunology Cancer
ABC1183 is an orally active selective dual GSK3 and *CDK9* inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC₅₀ values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities .

HY-151984

CDK9-IN-22	CDK	Cancer
CDK9-IN-22 is a potent *CDK9* inhibitor with IC₅₀s of 10.4, 876.2 nM for CDK9, CDK, respectively. CDK9-IN-22 induces apoptosis and cell cycle arrests at G2/M phase. CDK9-IN-22 decreases the expression of p-RNAPII (S2) and CDK9 protein. CDK9-IN-22 shows antiproliferative and aiti-tumor activity .

HY-179023

CDK9-IN-45	CDK Apoptosis Reactive Oxygen Species (ROS) Caspase Bcl-2 Family c-Myc IAP	Cancer
CDK9-IN-45 (Compound B11) is a highly selective *CDK9* inhibitor with IC₅₀ values for CDK9 and CDK1 of 7.13 and 489.5 nM respectively. CDK9-IN-45 exhibits a potent inhibitory effect on colorectal cancer cells. CDK9-IN-45 induces cell apoptosis and leads to significant accumulation of ROS. CDK9-IN-45 activates Caspase-3, downregulates Mcl-1, XIAP, and c-Myc. CDK9-IN-45 can be used for research on colorectal cancer .

HY-170978

PROTAC CDK9 degrader-11	PROTACs CDK	Cancer
PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC degrader for *CDK9* with DC₅₀ of 1.09 nM. PROTAC CDK9 degrader-11 exhibits cytotoxicity in multi small cell lung cancer cell with IC₅₀ of nanomolar levels. PROTAC CDK9 degrader-11 arrests cell cycle at G0/G1 phase, inhibits the cell invasion in DMS114 and DMS53 cell. PROTAC CDK9 degrader-11 exhibits antitumor efficacy in NCI-H446 xenograft mouse models .(Pink: ligand for target protein CDK9 ligand 3 (HY-170979); Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56 (HY-W247437))

HY-111356

IIIM-290	CDK	Cancer
IIIM-290 is a potent and oral CDK inhibitor with IC₅₀s of 90 and 94 nM for CDK2/A and CDK9/T1.

HY-156795

PROTAC CDK9/CycT1 Degrader-2	CDK	Cancer
PROTAC CDK9/CycT1 Degrader-2 is a inhibitor of *CDK9, with the IC₅₀* of 45 nM .

HY-130001

CDK9-IN-9	CDK	Cancer
CDK9-IN-9 (example 2) is a potent and selective *CDK9* inhibitor with an IC₅₀ of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC₅₀ of 155 nM. CDK9-IN-9 has anti-cancer activity .

HY-176736

CDK9-IN-40	CDK Apoptosis	Cancer
CDK9-IN-40 is a potent and orally active *CDK9* inhibitor with an IC₅₀ of 5.5 nM. CDK9-IN-40 shows high selectivity for *CDK9* versus CDK1, CDK2, CDK4, and CDK6, respectively. CDK9-IN-40 can arrest cell cycle, induce cell apoptosis and inhibit tumor growth. CDK9-IN-40 exhibits strong anti-cancer activity .

HY-147026

CDK9-IN-15	CDK	Cancer
CDK9-IN-15 (compound 50) is a potent *CDK9* inhibitor .

HY-157980

CDK9-IN-32	CDK	Cancer
CDK9-IN-32 (compound 006-3) is a *CDK9* inhibitor .

HY-178499

CDK9-IN-44	CDK c-Myc Bcl-2 Family	Neurological Disease Cancer
CDK9-IN-44 (Compound 7) is a selective *CDK9* inhibitor (IC₅₀=7.6 μM). CDK9-IN-44 inhibits CDK9/cyclin T1 kinase activity, blocking transcriptional elongation, reducing the expression of pro-cancer proteins (such as MCL1, c-MYC), and inducing tumor cell apoptosis. CDK9-IN-44 is promising for research of glioblastoma (GBM) and central nervous system (CNS) disorders .

HY-156296

CDK9-Cyclin T1 PPI-IN-1	CDK Apoptosis	Cancer
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective CDK9-Cyclin T1 protein-protein interaction (PPI) inhibitor. CDK9-Cyclin T1 PPI-IN-1 inhibits cell proliferation in TNBC MDA-MB-231 cells (IC₅₀: 0.044 μM), and induces apoptosis. CDK9-Cyclin T1 PPI-IN-1 inhibits CDK9 transcription activity, reduces the phosphorylation of RNA Pol II CTD ser2. CDK9-Cyclin T1 PPI-IN-1 inhibits tumor growth in a TNBC 4T1 mouse model .

HY-176484

CDK9-IN-39	CDK Apoptosis	Cancer
CDK9-IN-39 (1-7a-B1) is an orally active cyclin-dependent kinase 9 (CDK9) inhibitor with an IC₅₀ of 6.51 nM. CDK9-IN-39 induces cell apoptosis by inhibiting the phosphorylation of RNA polymerase II at Ser2 and can be used for study of colorectal cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-103248

Toyocamycin 5+ Cited Publications Vengicide	Infection Microorganisms Classification of Application Fields Antibiotics Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification	IRE1 Fungal Antibiotic Apoptosis CDK
Toyocamycin (Vengicide) is an adenosine analog produced by Streptomyces diastatochromogenes, acts as an XBP1 inhibitor. Toyocamycin blocks RNA synthesis and ribosome function, and induces apoptosis. Toyocamycin affects IRE1α-XBP1 pathway, and inhibits XBP1 mRNA cleavage with an IC₅₀ value of 80 nM with affecting IRE1α auto-phosphorylation. Toyocamycin specifically inhibits *CDK9* with an IC₅₀ value of 79 nM .

HY-N1127

Tricin 5+ Cited Publications	Infection Flavonoids Classification of Application Fields Flavones Agrostidoideae Phenols Polyphenols Plants Disease Research Fields Triticum aestivum L. Source Classification	CMV
Tricin is a natural flavonoid found in large amounts in wheat. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells by upregulating the expression of FAK-targeting microRNA-7 .

HY-N1127R

Tricin (Standard)	Structural Classification Flavonoids Flavones Agrostidoideae Phenols Polyphenols Plants Triticum aestivum L. Source Classification	Reference Standards CMV
Tricin (Standard) is the analytical standard of Tricin. This product is intended for research and analytical applications. Tricin is a natural flavonoid found in large amounts in wheat. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells by upregulating the expression of FAK-targeting microRNA-7 .

HY-103248R

Toyocamycin (Standard) Vengicide (Standard)	Structural Classification Microorganisms Antibiotics Antibacterial Disease Research Other Antibiotics Source Classification	Reference Standards IRE1 Fungal Antibiotic Apoptosis CDK
DL-Aspartic acid (Standard) is the analytical standard of DL-Aspartic acid. This product is intended for research and analytical applications. DL-Aspartic acid (DL-Asp-OH) is a kind of biological materials or organic compounds that are widely used in life science research .

Cat. No.	Product Name	Chemical Structure

HY-N1127S

Tricin-d6
Tricin-d₆ is the deuterium labeled Tricin . Tricin is a natural flavonoid present in large amounts in Triticum aestivum. Tricin can inhibit human cytomegalovirus (HCMV) replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells via the upregulation of focal-adhesion-finase (FAK)-targeting microRNA-7 .

HY-176174S

CDK2-IN-46
CDK2-IN-46 (compound 5g) is a selective CDK2 inhibitor with an IC₅₀ of 0.3 nM. CDK2-IN-46 has a selectivity of >200-fold for CDK1, CDK7, CDK9, CDK4, and CDK6. CDK2-IN-46 shows improves rat and cyno pharmacokinetic profiles .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks